Drazen J M
Harvard Medical School, Boston, USA.
Hosp Pract (1995). 1998 Feb 15;33(2):25-6, 31-3, 36-8. doi: 10.1080/21548331.1998.11443632.
A new generation of biologically informative treatments has altered our understanding of the disease--transforming what used to be viewed as a single entity into a family of airway disorders driven by different proinflammatory mediators. Although inhaled corticosteroids have been the treatment of choice for most patients, research is increasingly aimed at developing inhibitors targeted to specific effector systems.